Gerben J.C. Zwezerijnen

About

Gerben J.C. Zwezerijnen is a leading researcher in nuclear medicine and oncological imaging, with a primary focus on prostate cancer diagnostics. His work centers on the clinical application of PSMA-targeted PET/CT and PET/MRI to improve the detection and staging of prostate cancer. Dr. Zwezerijnen has made pivotal contributions through landmark clinical trials, including the SALT trial (106 citations), which demonstrated the superior accuracy of 18F-DCFPyL PET/CT for pelvic lymph-node staging compared to conventional imaging. He also led the DeTeCT trial (47 citations), exploring the feasibility of PSMA-targeted biopsies by correlating PET/CT findings with radical prostatectomy histopathology. Additionally, his ProStaPET study (27 citations) prospectively compared PSMA-PET/MRI against multiparametric MRI, showing enhanced detection of clinically significant prostate cancer. Collectively, his work has advanced precision staging, reduced unnecessary surgeries, and guided biopsy strategies. With over 180 total citations, Dr. Zwezerijnen’s research is instrumental in shaping modern, image-guided management of prostate cancer, bridging the gap between molecular imaging and personalized treatment.

Research Focus

Key Achievements

Top Papers

1. 1
   Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -

   106 citations · 2020
2. 2
   Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial

   47 citations · 2020
3. 3
   Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study

   27 citations · 2021

Key Collaborators

Contact & Links